MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

214.35 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Jan 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9
...
92 93 Next >
News headline image
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever ↗
Income investors can rely on these stocks. 
Via The Motley Fool
Topics Intellectual Property
News headline image
The Smartest Dividend Stocks to Buy in 2026 With $1,000 Right Now -- Including Realty Income and AbbVie ↗
These stocks sport dividend yields ranging from 2.9% to 5.5%. 
Via The Motley Fool
News headline image
Could Buying This Stock Today Pay Off Big Over the Next 5 Years? ↗
This healthcare giant is a top pick for growth and dividend investors. 
Via The Motley Fool
Topics Intellectual Property
News headline image
AbbVie Call Options Spike 2,599%: Tracking the Big Bet ↗
Via MarketBeat
AbbVie Seeks To Grow Obesity Drug Portfolio — Retail Touts Drugmaker As Big Competition To Lilly ↗
Via Stocktwits
News headline image
Genmab Reports Mixed Results From Late-Stage Trial Of Lymphoma Drug ↗
Epcoritamab demonstrated an improvement in progression-free survival in certain patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma, the company said. 
Via Stocktwits
News headline image
3 Absurdly Cheap Growth Stocks to Buy in 2026 ↗
These stocks could have plenty of upside for investors who invest in these businesses today. 
Via The Motley Fool
News headline image
Healthcare Titan Ascendant: Johnson & Johnson Hits All-Time Highs as It Navigates a New Political and Clinical Era
As of January 15, 2026, Johnson & Johnson (NYSE: JNJ) has emerged as the undisputed pacesetter of the healthcare sector, with its stock price surging to an all-time high of $218.53. This milestone... 
Via MarketMinute
Topics Artificial Intelligence Bankruptcy Earnings
News headline image
Nasdaq, S&P 500 Futures Edge Lower Ahead Of CPI, JPMorgan Earnings: Why MSFT, NVDA, ABBV, ABAT Are Also On Traders' Radar Today ↗
Retail sentiment remained mixed on Stocktwits, with a neutral view on SPY but growing bullishness around QQQ. 
Via Stocktwits
Topics Artificial Intelligence Credit Cards ETFs
News headline image
Revolution Medicines Dismisses Merck, Abbvie Buyout Talks While Analyst Say It Is Worth More Than $32B ↗
When asked about the company’s strategic transactions, CEO Mark Goldsmith said at a conference that the company has a policy of not commenting on rumors or speculation. 
Via Stocktwits
News headline image
The AI-Bio Convergence: Lilly and Nvidia Kick Off JPM26 with Landmark $1 Billion Alliance
The 44th Annual J.P. Morgan Healthcare Conference opened today in San Francisco with an intensity not seen in years, as the healthcare and technology sectors officially merged their futures. The... 
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
News headline image
3 No-Brainer Dividend Stocks to Buy Right Now ↗
The decision about buying these dividend stocks is an easy one. 
Via The Motley Fool
Topics Intellectual Property
News headline image
This ETF Is Proof That the Healthcare Rebound Is Real ↗
Via MarketBeat
Topics ETFs
News headline image
Eli Lilly Solidifies Immunology Dominance with $1.2 Billion Acquisition of Ventyx Biosciences
In a move that underscores the tightening intersection between metabolic health and systemic inflammation, Eli Lilly and Company (NYSE: LLY) officially announced on January 7, 2026, its definitive... 
Via MarketMinute
News headline image
2 Healthcare Stocks That Can Diversify a Tech-Heavy Portfolio ↗
Add some stability to your holdings with these healthcare giants. 
Via The Motley Fool
Topics Economy Intellectual Property Lawsuit
News headline image
MoonLake Immunotherapeutics Surges as FDA "De-Risks" Sonelokimab, Reigniting Multi-Billion Dollar Takeover Speculation
MoonLake Immunotherapeutics (NASDAQ: MLTX) shares have experienced a dramatic resurgence this week, climbing over 40% following a pivotal regulatory update that has effectively cleared the path for its... 
Via MarketMinute
Topics Intellectual Property
News headline image
The $20 Billion Question: Revolution Medicines Surges as Big Pharma Circles the Pan-RAS Leader
The first week of 2026 has set the biotech sector ablaze, with Revolution Medicines (NASDAQ: RVMD) finding itself at the epicenter of a high-stakes acquisition tug-of-war. Shares of the Redwood... 
Via MarketMinute
Topics Intellectual Property
News headline image
1 Unpopular Stock That Deserves a Second Chance and 2 We Question
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps... 
Via StockStory
News headline image
Ironwood Pharmaceuticals’ 2026 Guidance Shock Sparks a Major Re-Rating ↗
Via MarketBeat
News headline image
Revolution Medicines Stock Soars On Report Of AbbVie Takeover ↗
The Wall Street Journal reported on Wednesday, citing people familiar with the matter, that AbbVie is in advanced talks to buy Revolution Medicines, while adding it couldn’t learn how much AbbVie is... 
Via Stocktwits
News headline image
Red Spruce Capital Nets $3.7 Million by Dumping One-Third of BSCR Shares ↗
Invesco BulletShares 2027 Corporate Bond ETF targets investment grade U.S. corporate bonds maturing in 2027 for predictable income exposure. 
Via The Motley Fool
Topics Bonds ETFs Regulatory Compliance
News headline image
3 Healthcare Stocks with Exciting Potential
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have benefited from elevated demand, and their... 
Via StockStory
Topics Stocks
Top S&P500 movers in Monday's session ↗
Via Chartmill
News headline image
Flu Season's Here—This Dividend-Payer Controls the Shot Market ↗
Via MarketBeat
Topics Artificial Intelligence Death
Uncover the latest developments among S&P500 stocks in today's session. ↗
Via Chartmill
News headline image
26 Top Dividend Stocks to Buy and Hold in 2026 ↗
Another year, another long list of great dividend stocks. 
Via The Motley Fool
Topics Intellectual Property
News headline image
GH Research Stock Grabs Retail Spotlight Ahead Of FDA Update On Depression Treatment ↗
GH001 showed symptom improvement, high remission rates, and sustained benefits in a Phase 2b trial for treatment-resistant depression. 
Via Stocktwits
News headline image
Take Warren Buffett's Advice: Don't Buy Any Stock in 2026 Unless It Passes This Test ↗
Buffett is no longer at the helm of Berkshire Hathaway. But his investing wisdom remains relevant. 
Via The Motley Fool
News headline image
Buying This Healthcare Stock Could Make You a Millionaire Retiree ↗
It won't happen overnight, but patience will be rewarded. 
Via The Motley Fool
Topics Intellectual Property Retirement
News headline image
The Evolution of a Healthcare Giant: Abbott Laboratories (ABT) 2026 Stock Feature
As of today, January 1, 2026, Abbott Laboratories (NYSE: ABT) stands as one of the most resilient and strategically diversified giants in the global healthcare landscape. While the broader market has... 
Via PredictStreet
Topics Economy Lawsuit World Trade
< Previous 1 2 3 4 5 6 7 8 9
...
92 93 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story